Quarterly Updates23 May 2026, 05:51 pm
SMS Pharma FY26 PAT Up 48% to ₹102 Cr
AI Summary
SMS Pharmaceuticals Ltd reported a 48% YoY increase in PAT to ₹102 crore for FY26, driven by backward integration and product mix. EBITDA margin expanded by 155 bps YoY to 19%. Revenue grew by 13% YoY to ₹886.87 crore. The company's board recommended a final dividend of ₹0.40 per share. SMS Pharma anticipates over 15% revenue growth with EBITDA margins around 20% in FY27. VKT Pharma, an associate company, contributed ₹14 crores to the FY26 PAT.
Key Highlights
- FY26 PAT grew 48% YoY to ₹102 crore, including VKT Pharma's share.
- FY26 EBITDA margin increased by 155 bps YoY to 19%.
- FY26 revenue grew 13% YoY to ₹886.87 crore.
- A final dividend of ₹0.40 (40%) per share was recommended.
- Company expects over 15% revenue growth with 20% EBITDA margins in FY27.
Price Impact
More from SMSPHARMA